Physician profile
Simeon Jaggernauth
NPI 1083667737
$115,806.39
in general payments reported to CMS, 2019-2025
42 companies · $1,223 in 2025
The $1,223 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31K · 2020: $23K · 2021: $14K · 2022: $36K · 2023: $10K · 2024: $442 · 2025: $1,223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,893 · Food and Beverage: $2,153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,893.00 |
| Food and Beverage | $2,153.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $86,315.32 | 2019-2025 | Opdivo |
| Celgene Corporation | $21,425.48 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $1,276.64 | 2019-2025 | Keytruda |
| Astrazeneca Pharmaceuticals LP | $865.81 | 2019-2025 | Imfinzi, Calquence, Enhertu |
| Novartis Pharmaceuticals Corporation | $645.46 | 2019-2025 | |
| Amgen INC. | $604.21 | 2019-2022 | |
| Pfizer INC. | $577.97 | 2019-2025 | |
| Eisai INC. | $541.42 | 2019-2025 | |
| Janssen Biotech, INC. | $378.40 | 2019-2025 | Rybrevant, Carvykti, Erleada |
| Lilly USA, LLC | $355.29 | 2019-2025 | Verzenio, Jaypirca |
| Rigel Pharmaceuticals, INC. | $274.60 | 2020-2021 | |
| Daiichi Sankyo INC. | $235.59 | 2024-2025 | Enhertu, Datroway |
| Genzyme Corporation | $221.18 | 2019-2025 | |
| Abbvie INC. | $220.19 | 2024-2025 | |
| Coherus Oncology, INC. | $194.17 | 2020-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simeon Jaggernauth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.